CSC-derived EVs are likely to interact with immune cells enriched in the CSC niche, including MHC-II expressing macrophages and programmed cell death 1 (PD1) positive T cells, potentially promoting tumor progression through immunosuppression (30). The gene discussed is PDCD1; the disease is neoplasm.